PNH Drugs
Jan 26, 2024
AstraZeneca Strengthens Presence in PNH Treatment with Voydeya in Japan: World’s First Approval
A month following Novartis’ foray into the paroxysmal nocturnal hemoglobinuria (PNH) treatment domain, AstraZeneca strengthens its position in this field as its latest contender, Voydeya, secures a groundbreaking approval in Japan. Voydeya (danicopan), an innovative oral factor D inhibitor, has received approval fr...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
